Integration of inflammation and cancer by molecular chaperone

分子伴侣整合炎症和癌症

基本信息

  • 批准号:
    10056559
  • 负责人:
  • 金额:
    $ 16.12万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2017
  • 资助国家:
    美国
  • 起止时间:
    2017-01-01 至 2021-12-31
  • 项目状态:
    已结题

项目摘要

Project Summary Chronic and unrelenting inflammation contributes unequivocally to oncogenesis. However, there are many fundamental challenges in the field of onco-inflammation. Among them, systematic study has not been done to quantitatively and qualitatively identify and characterize the type of inflammations that is particularly oncogenic. We hypothesize that oncogenic inflammation is genotoxic and modulated by key innate immune receptors such as Toll-like receptors (TLRs) in a cell type-specific fashion (Hypothesis 1). In addition, despite the extensive study of the cancer genome, fewer studies have addressed the roles of protein quality control in inflammation and oncogenesis. Cancer cells, as compared to normal cells, have a high metabolic demand which increases the need for protein chaperones that accelerate protein folding. We thus propose that there is a cancer-specific HSP-client network that plays pivotal roles in inflammation and cancer (Hypothesis 2). Molecular chaperone gp96 is a paralogue of HSP90 in the endoplasmic reticulum. It is uniformly expressed at a high level in human cancers, and the high expression of gp96 correlates with worse prognosis. Intriguingly, we discovered that gp96 is an obligated master chaperone for TLRs. We further revealed that deletion of gp96 in Mφs protect mice against colitis-associated colon cancer, which correlates with a reduced cytokine level and protection against mutation of Ctnnb1 encoding β-catenin. We have also generated cell type-specific gp96 KO mice by deleting gp96 in B cells, regulatory T cells, gut epithelial cells, platelets and dendritic cells. These unique models allow us to quantify the extent of contribution by these immune cell subsets to inflammation- associated cancer. In addition, we have shown that gp96 plays essential roles in chaperoning several other strategically important clients in oncogenesis, including integrins, Wnt co-receptor, Her2, IGF-1 and surface TGFβ docking receptor LRRC32 (GARP). Our findings suggest that gp96 drives oncogenesis by integrating cell-intrinsic oncogenic client network with inflammation (Hypothesis 3). We will address our hypotheses by first determining if oncogenic inflammation is modulated by the TLR master chaperone gp96 in a cell type-specific fashion, using a battery of unique genetic tools. We will then complete the high resolution mapping of cancer- specific gp96-client network via genetic, pharmacological and biochemical means. The ultimate goal of this US-China joint project (RFA-AI-16-006) is to uncover both cancer-intrinsic and cancer- extrinsic roles of gp96 in oncogenesis to guide the development of novel cancer therapeutics in the future.
项目概要 慢性且持续的炎症无疑会导致肿瘤发生。然而,有很多 肿瘤炎症领域的根本挑战。其中,尚未进行系统研究 定量和定性地识别和表征特别致癌的炎症类型。 我们假设致癌炎症具有基因毒性并受到关键先天免疫受体的调节 例如细胞类型特异性的 Toll 样受体 (TLR)(假设 1)。此外,尽管 对癌症基因组的广泛研究,很少有研究探讨蛋白质质量控​​制在癌症中的作用 炎症和肿瘤发生。与正常细胞相比,癌细胞具有较高的代谢需求 这增加了对加速蛋白质折叠的蛋白质伴侣的需求。因此我们建议有 癌症特异性 HSP 客户网络在炎症和癌症中发挥关键作用(假设 2)。 分子伴侣 gp96 是内质网中 HSP90 的旁系同源物。统一表示为 gp96 在人类癌症中水平较高,并且 gp96 的高表达与较差的预后相关。有趣的是, 我们发现 gp96 是 TLR 的义务主伴侣。我们进一步揭示了 gp96 的删除 Mφs 可以保护小鼠免受结肠炎相关结肠癌的侵害,这与细胞因子水平降低和 防止编码 β-catenin 的 Ctnnb1 突变。我们还生成了细胞类型特异性 gp96 KO 通过删除 B 细胞、调节性 T 细胞、肠上皮细胞、血小板和树突状细胞中的 gp96 来对小鼠进行实验。这些 独特的模型使我们能够量化这些免疫细胞亚群对炎症的贡献程度—— 相关癌症。此外,我们还表明 gp96 在陪伴其他几种药物方面发挥着重要作用。 在肿瘤发生过程中具有重要战略意义的客户,包括整合素、Wnt 共受体、Her2、IGF-1 和表面蛋白 TGFβ 对接受体 LRRC32 (GARP)。我们的研究结果表明 gp96 通过整合来驱动肿瘤发生 细胞内在致癌客户网络与炎症(假设 3)。我们将首先解决我们的假设 确定细胞类型特异性中的致癌炎症是否由 TLR 主伴侣 gp96 调节 时尚,使用一系列独特的遗传工具。然后我们将完成癌症的高分辨率绘图—— 通过遗传、药理学和生化手段特定的 gp96-客户网络。 这个中美联合项目 (RFA-AI-16-006) 的最终目标是揭示癌症本质和癌症- gp96 在肿瘤发生中的外在作用,以指导未来新型癌症疗法的开发。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Zihai Li其他文献

Zihai Li的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Zihai Li', 18)}}的其他基金

Sexual Dimorphism in T Cell Exhaustion and Bladder Cancer
T 细胞耗竭和膀胱癌中的性别二态性
  • 批准号:
    10629078
  • 财政年份:
    2023
  • 资助金额:
    $ 16.12万
  • 项目类别:
Targeting GRP94-TGF-beta Pathway for Cancer Immunotherapy Supplement
靶向 GRP94-TGF-β 通路的癌症免疫治疗补充剂
  • 批准号:
    10818173
  • 财政年份:
    2021
  • 资助金额:
    $ 16.12万
  • 项目类别:
Targeting GRP94-TGF-beta Pathway for Cancer Immunotherapy
靶向 GRP94-TGF-β 通路的癌症免疫治疗
  • 批准号:
    10474548
  • 财政年份:
    2021
  • 资助金额:
    $ 16.12万
  • 项目类别:
Targeting GRP94-TGF-beta Pathway for Cancer Immunotherapy
靶向 GRP94-TGF-β 通路的癌症免疫治疗
  • 批准号:
    10689068
  • 财政年份:
    2021
  • 资助金额:
    $ 16.12万
  • 项目类别:
Targeting GRP94-TGF-beta Pathway for Cancer Immunotherapy
靶向 GRP94-TGF-β 通路的癌症免疫治疗
  • 批准号:
    10275810
  • 财政年份:
    2021
  • 资助金额:
    $ 16.12万
  • 项目类别:
Endoplasmic Reticulum Chaperones in Cancer Biology and Therapy
癌症生物学和治疗中的内质网伴侣
  • 批准号:
    9321008
  • 财政年份:
    2015
  • 资助金额:
    $ 16.12万
  • 项目类别:
Project 1: Definition of grp94-GARP-TGFbeta Axis in Cancer Biology and Clinical Significance
项目1:grp94-GARP-TGFbeta轴在癌症生物学中的定义及其临床意义
  • 批准号:
    8934513
  • 财政年份:
    2015
  • 资助金额:
    $ 16.12万
  • 项目类别:
Novel mechanisms of UPR sensing and nonalcoholic fatty liver disease
UPR传感和非酒精性脂肪肝的新机制
  • 批准号:
    9026108
  • 财政年份:
    2015
  • 资助金额:
    $ 16.12万
  • 项目类别:
Endoplasmic Reticulum Chaperones in Cancer Biology and Therapy
癌症生物学和治疗中的内质网伴侣
  • 批准号:
    8934510
  • 财政年份:
    2015
  • 资助金额:
    $ 16.12万
  • 项目类别:
Endoplasmic Reticulum Chaperones in Cancer Biology and Therapy
癌症生物学和治疗中的内质网伴侣
  • 批准号:
    9770790
  • 财政年份:
    2015
  • 资助金额:
    $ 16.12万
  • 项目类别:

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    $ 16.12万
  • 项目类别:
    Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    $ 16.12万
  • 项目类别:
    Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    $ 16.12万
  • 项目类别:
    Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 16.12万
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    $ 16.12万
  • 项目类别:
    Standard Grant
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    $ 16.12万
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    $ 16.12万
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 16.12万
  • 项目类别:
    EU-Funded
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 16.12万
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    $ 16.12万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了